Edition:
United Kingdom

Second Sight Medical Products Inc (EYES.OQ)

EYES.OQ on NASDAQ Stock Exchange Capital Market

2.35USD
12 Dec 2017
Change (% chg)

$0.35 (+17.50%)
Prev Close
$2.00
Open
$2.04
Day's High
$2.54
Day's Low
$2.04
Volume
644,526
Avg. Vol
84,927
52-wk High
$2.82
52-wk Low
$0.90

Chart for

About

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company's product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that... (more)

Overall

Beta: --
Market Cap(Mil.): $65.31
Shares Outstanding(Mil.): 56.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.16 16.44
EPS (TTM): -- -- --
ROI: -- 14.01 10.62
ROE: -- 16.85 14.20

BRIEF-SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION SYSTEM

* SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE ORION CORTICAL VISUAL PROSTHESIS SYSTEM

08 Nov 2017

BRIEF-Second Sight Medical Products reports Q3 loss per share $0.12

* Second Sight Medical Products Inc - qtrly adjusted loss per share $0.11 Source text for Eikon: Further company coverage:

02 Nov 2017

BRIEF-Second Sight receives FDA approval to begin first Orion human clinical study

* Second Sight receives full FDA approval to begin first Orion human clinical study

02 Nov 2017

BRIEF-Second Sight Medical Products files for mixed shelf of upto $100 mln‍​

* Second Sight Medical Products Inc files for mixed shelf of upto $100 million - sec filing‍​ Source text : http://bit.ly/2gXz4DE Further company coverage:

31 Oct 2017

BRIEF-Second sight receives German approval to begin study to implant and evaluate Argus II in better-sighted retinitis pigmentosa patients

* Second Sight receives approval from Bundesinstitut Für Arzneimittel Und Medizinprodukte in Germany to begin study to implant and evaluate Argus II in better-sighted retinitis pigmentosa patients Source text for Eikon: Further company coverage:

17 Oct 2017

BRIEF-Second Sight receives conditional FDA approval to begin first Orion human clinical study

* Second sight receives conditional FDA approval to begin first Orion human clinical study

28 Aug 2017

BRIEF-Second Sight Medical Products Q2 sales $2.2 mln

* Says total revenue was $2.2 million for q2 of 2017, compared with $1.0 million in q2 of 2016 Source text for Eikon: Further company coverage:

01 Aug 2017

BRIEF-Second Sight Medical Products submits application for IDE with FDA

* Second Sight Medical Products - submitted application for IDE with FDA for approval to conduct early feasibility study of orioncortical visual prosthesis system

18 Jul 2017

BRIEF-Second Sight Medical Products says Thomas Miller notified company he was submitting his resignation as CFO

* Second Sight Medical Products Inc - On June 20, 2017, Thomas B. Miller, CFO notified company he was submitting his resignation as Chief Financial Officer

26 Jun 2017

Earnings vs. Estimates